Clinical trials
catalyst calendar across sponsors →Studies where JBIO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 12 tracked-famous managers (CITADEL ADVISORS LLC, Balyasny Asset Management L.P., MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., +7 more) · FINRA short interest 11.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07541287Incidence of treatment-emergent adverse events (safety and tolerability)Open-label · Treatment | Phase 2 | Recruiting | Drug: JADE101 | IgA Nephropathy | 30 | Jan 2029 | ≤ 896 d | 2026-07-07 |
| A Phase 1 Study of JADE201 in Participants With Rheumatoid ArthritisNCT07533955Safety and Tolerability of Single Ascending Doses of JADE201 in participants with Rheumatoid ArthritisRandomized · Double-masked · Basic science | Phase 1 | Recruiting | Drug: JADE201, Placebo | Rhematoid Arthritis | 36 | Oct 2027 | ≤ 438 d | 2026-06-01 |
| A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese ParticipantsNCT07525947Safety and tolerability of single dose of JADE101 in healthy Japanese and Chinese participantsNon-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: JADE101 | Healthy Volunteers (HV) | 40 | May 2027 | ≤ 285 d | 2026-06-04 |
| A Phase 1 Study of JADE101 in Healthy ParticipantsNCT07059312Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy ParticipantsRandomized · Double-masked · Basic science | Phase 1 | Active, not recruiting | Drug: JADE101, Placebo | Healthy Volunteers | 32 | Oct 2026 | ≤ 73 d | 2025-12-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19